CRISPR Therapeutics AG 1Q 2026: Revenue $1.458M, EPS $(1.28) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.
CRISPR Therapeutics AG reported Q1 2026 results with revenue of $1.458M, a net loss of $(122.931) M, and diluted EPS of $(1.28). Revenue increased by 68.5% year-over-year. The company narrowed its net loss from $(135.996) M in Q1 2025. Key highlights include product approvals for CASGEVY, advancements in LNP and SyNTase platforms, and ongoing trials for sickle cell disease and type 1 diabetes. Strategic partnerships with Vertex and Sirius are enhancing co-development efforts. Continued investment in manufacturing and R&D is prioritized across four core franchises.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments